Describes a standardized experimental workflow for orthohantavirus production, infection detection, and antiviral screening, enabling more reproducible comparative assays.

Develops biocompatible polylactide- and chitosan-based nanocarriers intended to improve antiretroviral delivery.

Shows that Puumala virus infection remodels P-bodies and the cytoskeleton, linking cell-state reorganization to orthohantavirus infection biology.

Demonstrates that roxadustat amplifies inflammatory signaling and metabolic rewiring in human leukocytes by altering oxygen-sensing pathways.

Identifies FDA-approved drug candidates that inhibit the coronavirus methyltransferase nsp16 across SARS-CoV-2, SARS-CoV-1, and MERS-CoV.

Shows that the glucocorticoid receptor modulator AZD9567 can reactivate latent HIV-1.

Identifies a natural-product-derived compound with potential broad-spectrum coronavirus entry-inhibitory activity through virtual screening and validation.

Defines myocardial transcriptomic signatures at sudden death that may mark tissue vulnerable to lethal arrhythmias.

Identifies nitrile-containing isoquinoline-related natural product derivatives that inhibit coronavirus entry in silico and in vitro.

Shows that HIV-infected microglia generate neuroinflammation that drives neuronal dysfunction and death in human brain organoids.

Identifies the hypoxia-regulated ectonucleotidase CD73 as a host determinant that helps shape HIV latency.

Reviews how modern fluorescence microscopy approaches can advance orthohantavirus research.

Shows that the bovine seminal plasma protein PDC-109 has broad antiviral activity.

Implicates the chemokine CCL2 in promoting early establishment of the latent HIV reservoir.

Maps calcium-interacting sites in HIV gp41 and links them to the membrane fusion mechanism.

Characterizes the intracellular dynamics and localization behavior of hantavirus nucleocapsid protein.

Describes a dual-function fusion protein that blocks both IL-6 trans-signaling and SARS-CoV-2 cellular infection.

Evaluates a new class of AKT/mTOR activators as HIV latency-reversing agents in ex vivo and in vivo settings.